Pamoic acid disodium salt, a supposedly inactive component in many formulations of drugs used to modulate release, is a potent agonist of the orphan receptor GPR35. GPR35 is a class A, rhodopsin-like G protein-coupled receptor (GPCR), strongly expressed in the lower intestine and colon, dorsal root ganglia, as well as a variety of immune cells including monocytes and dendritic cells. Targeting GPR35 provides potential therapeutic opportunities in a range of conditions, such as inflammation, pain and cancer.?
References:
1.?Zhao P, Sharir H, Kapur A, et al. Targeting of the orphan receptor GPR35 by pamoic acid: a potent activator of extracellular signal-regulated kinase and β-arrestin2 with antinociceptive activity. Molecular Pharmacology, 2010, 78(4): 560-568.
2.?Quon T, Lin LC, Ganguly A, et al. Therapeutic Opportunities and Challenges in Targeting the Orphan G Protein-Coupled Receptor GPR35. ACS Pharmacology & Translational Science, 2020, 3(5): 801-812.
